{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2624252"],"location":["Japan"],"study_start_month":["6"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Randomized Phase II Study of BSC vs Cetuximab vs Irinotecan and Cetuximab in Patients with KRAS codon G13D mutant Metastatic Colorectal Cancer (G13 study)","description":"Interventions: Cetuximab\nCetuximab+Irinotecan\nBSC\nPrimary outcome(s): Progression Free Survival\nStudy Design: Parallel Randomized","dates":{"creation":"2012-06-15"},"accession":"2624252","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000008850"]}}